

# Long-Acting Therapeutics For Chronic Diseases



*Peptron is a biotech company developing a wide range of peptide and small molecule based drugs to treat chronic and life-threatening disorders. Its initial focus is to provide long-term cure for neurodegenerative, cancer and endocrine related diseases.*

## Our Vision, Mission and Goal



Our mission is to develop premier and patient-friendly medicines that can sustain a leading position in an ever increasingly competitive marketplace. To achieve this goal at Peptron, we have devoted ourselves to developing innovative products of high-caliber featuring a variety of competitive advantages. The resulting drug delivery system that was finally established is our unique **SmartDepot™ platform technology**.

Based on this technology, Peptron has been actively developing various sustained release (SR) drugs to enhance patient's convenience and quality of health care. It can also improve medication adherence and treatment effect while significantly reducing the health care costs. Moreover, it will also extend the life cycle of the products and preserve their competitive advantages for longer periods thereby suppressing the emergence of competing products. These factors will ultimately contribute to the realization of higher profits for our partners.

## Pipeline



- SR-Exenatide for the treatment of type 2 diabetes mellitus (T2D).
- SR-Exenatide for the treatment of neurodegenerative diseases.
- SR-Leuprolide for the treatment of prostate cancer.
- SR-Octreotide for the treatment of acromegaly, which is analog of pituitary somatostatin.
- SR-Risperidone is a selective monoaminergic antagonist for the treatment of schizophrenia.

# SmartDepot™ Platform Technology

**Peptron's proprietary Ultrasonic Spray Drying Technology for the preparation of sustained release injectable PLGA formulation of drugs**

- High production yield & Controlled particle size.
- Adjusted drug release profiles: from weeks to several months.
- Throughout the process, no toxic organic solvent, such as methylene chloride, ethyl acetate, methanol, N-methylpyrrolidone and acetonitrile are used.
- Very simple, convenient, easy to scale-up and reproducible process.
- Applicable to produce sustained release formulations of peptides and small molecules, such as LHRH analogs, somatostatin analogs, GLP-1 analogs, etc.

***Peptron integrates the extensive experience of peptide research, drug development and expertise in drug delivery technologies for more than 15 years combined with a patients-focused approach driven by excellence.***

## SmartDepot™: Pipeline

SR Development Project	Preclinical	Phase 1	Phase 2	Phase 3	NDA/MA	Potential Market*
SR-Leuprolide / 1 month (Prostate cancer, Endometriosis)	<b>Generic</b>					\$2.4 B (In 2011)
SR-Leuprolide / 3 months (Prostate cancer, Endometriosis)	<b>Generic</b>					\$2.4 B (In 2011)
SR-Exenatide PT302 / 1&2 weeks (Type 2 diabetes)						\$1.9 B (In 2019)
SR-Exenatide PT304 / 1 month (Type 2 diabetes)						\$1.9 B (In 2019)
SR-Exenatide PT320&PT330 / 2 weeks (Parkinson/Alzheimer)						\$9.3 B (In 2011)
SR-Octreotide / 1 month (Acromegaly, Carcinoid tumor)	<b>Generic</b>		(BE)			\$1.2 B (In 2010)
SR-Risperidone / 2 weeks (Schizophrenia)	<b>Generic</b>					\$1.5 B (In 2010)

\* Estimates for potential market opportunities are based on publicly available information, research reports and company reports



**Peptron, Inc.**

37-24 Yuseong-daero 1628 beon-gil Yuseong-Gu 305-811 Daejeon, South Korea

Tel. +82-42-360-8820 Fax. +82-42-360-8888 Email. biz@peptron.com [www.peptron.com](http://www.peptron.com)